Comparative Pharmacology
Head-to-head clinical analysis: COLESTIPOL HYDROCHLORIDE versus LEROCHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLESTIPOL HYDROCHLORIDE versus LEROCHOL.
COLESTIPOL HYDROCHLORIDE vs LEROCHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
Oral: 10 mg once daily, taken at bedtime without regard to meals.
None Documented
None Documented
Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life.
Terminal elimination half-life: 12-18 hours. Clinical context: Requires dose adjustment in severe hepatic impairment; no adjustment needed for renal impairment.
Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs.
Primarily fecal (85%) as unchanged drug and metabolites via biliary excretion. Renal excretion accounts for 15%, mostly as glucuronide conjugates.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant